Hologic (NASDAQ:HOLX) Upgraded at BNP Paribas

BNP Paribas upgraded shares of Hologic (NASDAQ:HOLX) to a strong-buy rating in a report published on Tuesday,Zacks.com reports.

A number of other analysts have also commented on HOLX. Royal Bank of Canada boosted their target price on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Raymond James boosted their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and cut their price target for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Mizuho cut their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Hologic in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Hologic has a consensus rating of “Moderate Buy” and an average price target of $89.50.

Hologic Trading Down 0.6 %

Shares of HOLX stock opened at $75.09 on Tuesday. The stock’s fifty day moving average price is $79.45 and its two-hundred day moving average price is $78.56. The company has a market cap of $17.04 billion, a PE ratio of 22.55, a P/E/G ratio of 2.37 and a beta of 0.96. Hologic has a fifty-two week low of $69.36 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same quarter last year, the business posted $0.89 EPS. The company’s revenue was up 4.5% compared to the same quarter last year. Equities analysts predict that Hologic will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.75% of the company’s stock.

Hedge Funds Weigh In On Hologic

Institutional investors have recently bought and sold shares of the stock. State Street Corp increased its stake in shares of Hologic by 0.8% during the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after purchasing an additional 81,057 shares in the last quarter. FMR LLC increased its stake in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Hologic by 0.7% during the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock valued at $208,051,000 after purchasing an additional 18,774 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in shares of Hologic by 8.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after purchasing an additional 195,285 shares in the last quarter. Finally, Black Creek Investment Management Inc. increased its stake in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.